This week UCB announced positive and exciting first results of a Phase III study designed to evaluate the efficacy and safety of conversion to Vimpat® (lacosamide) monotherapy in adult epilepsy patients with partial-onset seizures with or without secondary generalization.
These new data support our development of Vimpat as monotherapy for partial onset seizures and our goal to make it available to many more people living with epilepsy worldwide. UCB plans to submit these data to the U.S. Food & Drug Administration during the second half of 2013 as part of our supplemental New Drug Application for Vimpat.
Vimpat is currently approved as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy (ages ≥ 17 years). It is available in 36 countries worldwide and has been used by over 230,000 patients.